Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 18 April 2008:
Vol. 320. no. 5874, pp. 373 - 376
DOI: 10.1126/science.1154315
Prev | Table of Contents | Next

Reports

Recapitulation of IVIG Anti-Inflammatory Activity with a Recombinant IgG Fc

Robert M. Anthony,1 Falk Nimmerjahn,1,4 David J. Ashline,2 Vernon N. Reinhold,2 James C. Paulson,3 Jeffrey V. Ravetch1*

It is well established that high doses of monomeric immunoglobulin G (IgG) purified from pooled human plasma [intravenous immunoglobulin (IVIG)] confer anti-inflammatory activity in a variety of autoimmune settings. However, exactly how those effects are mediated is not clear because of the heterogeneity of IVIG. Recent studies have demonstrated that the anti-inflammatory activity of IgG is completely dependent on sialylation of the N-linked glycan of the IgG Fc fragment. Here we determine the precise glycan requirements for this anti-inflammatory activity, allowing us to engineer an appropriate IgG1 Fc fragment, and thus generate a fully recombinant, sialylated IgG1 Fc with greatly enhanced potency. This therapeutic molecule precisely defines the biologically active component of IVIG and helps guide development of an IVIG replacement with improved activity and availability.

1 Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY 10021, USA.
2 Glycomics Center, Department of Biochemistry and Molecular Biology, University of New Hampshire, Durham, NH 03824, USA.
3 Departments of Chemical Physiology and Molecular Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
4 Laboratory of Experimental Immunology and Immunotherapy, University of Erlangen-Nuremberg, Erlangen 91054, Germany.

* To whom correspondence should be addressed. E-mail: ravetch{at}rockefeller.edu

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
The Role of Th17 in Neuroimmune Disorders: A Target for CAM Therapy. Part III.
A. Vojdani, J. Lambert, and G. Kellermann (2009)
Evid. Based Complement. Altern. Med.
   Abstract »    Full Text »    PDF »
Profile of Jeffrey Ravetch.
P. Downey (2009)
PNAS 106, 7689-7691
   Full Text »    PDF »
Impaired inhibitory Fc{gamma} receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy.
B. Tackenberg, I. Jelcic, A. Baerenwaldt, W. H. Oertel, N. Sommer, F. Nimmerjahn, and J. D. Lunemann (2009)
PNAS 106, 4788-4792
   Abstract »    Full Text »    PDF »
DC-SIGN and {alpha}2,6-sialylated IgG Fc interaction is dispensable for the anti-inflammatory activity of IVIg on human dendritic cells.
J. Bayry, K. Bansal, M. D. Kazatchkine, and S. V. Kaveri (2009)
PNAS 106, E24
   Full Text »    PDF »
Reply to Bayry et al.: The anti-inflammatory activity of sialylated IgG Fcs.
J. Ravetch, R. Anthony, F. Wermeling, and M. Karlsson (2009)
PNAS 106, E25
   Full Text »    PDF »
Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag.
P. Wu, W. Shui, B. L. Carlson, N. Hu, D. Rabuka, J. Lee, and C. R. Bertozzi (2009)
PNAS 106, 3000-3005
   Abstract »    Full Text »    PDF »
Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors.
S. L. Sazinsky, R. G. Ott, N. W. Silver, B. Tidor, J. V. Ravetch, and K. D. Wittrup (2008)
PNAS 105, 20167-20172
   Abstract »    Full Text »    PDF »
Inaugural Article: Identification of a receptor required for the anti-inflammatory activity of IVIG.
R. M. Anthony, F. Wermeling, M. C. I. Karlsson, and J. V. Ravetch (2008)
PNAS 105, 19571-19578
   Abstract »    Full Text »    PDF »
Improved Tumor Immunity Using Anti-Tyrosinase Related Protein-1 Monoclonal Antibody Combined with DNA Vaccines in Murine Melanoma.
Y. M. Saenger, Y. Li, K. C. Chiou, B. Chan, G. Rizzuto, S. L. Terzulli, T. Merghoub, A. N. Houghton, and J. D. Wolchok (2008)
Cancer Res. 68, 9884-9891
   Abstract »    Full Text »    PDF »
Crucial Role of Aspartic Acid at Position 265 in the CH2 Domain for Murine IgG2a and IgG2b Fc-Associated Effector Functions.
L. Baudino, Y. Shinohara, F. Nimmerjahn, J.-I. Furukawa, M. Nakata, E. Martinez-Soria, F. Petry, J. V. Ravetch, S.-I. Nishimura, and S. Izui (2008)
J. Immunol. 181, 6664-6669
   Abstract »    Full Text »    PDF »
Review: New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins.
M. Stangel (2008)
Therapeutic Advances in Neurological Disorders 1, 115-124
   Abstract »    PDF »
The Antiinflammatory IgG.
S. V. Kaveri, S. Lacroix-Desmazes, and J. Bayry (2008)
N. Engl. J. Med. 359, 307-309
   Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)